Information Provided By:
Fly News Breaks for March 4, 2020
Mar 4, 2020 | 16:49 EDT
Citi analyst Joanne Wuensch initiated coverage of Edwards Lifesciences with a Buy rating and $252 price target. The analyst said the focus of the company is on their TAVR and TMTT franchises -- which she called large, growing market opportunities -- noting that the TAVR market is expected to increase to reach $7B in 2024 from $4B today and the TMTT market expected to reach $3B in 2024 from $1B estimated in 2021.
News For EW From the Last 2 Days
There are no results for your query EW